 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | VK-2019 / The Wistar Institute, Stanford University
Enrollment change, Trial completion date, Trial primary completion date: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (clinicaltrials.gov) - Nov 4, 2024
P2, N=61, Recruiting, Sponsor: Stanford University
N=30 --> 61 | Trial completion date: Feb 2026 --> Feb 2031 | Trial primary completion date: Feb 2025 --> Feb 2028
- | NXP800 / Nuvectis Pharma
Enrollment open, Metastases: NXP800 for the Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Jun 3, 2024
P1, N=30, Recruiting, Sponsor: Mayo Clinic
N=30 --> 61 | Trial completion date: Feb 2026 --> Feb 2031 | Trial primary completion date: Feb 2025 --> Feb 2028 Not yet recruiting --> Recruiting
- | NXP800 / Nuvectis Pharma
New P1 trial, Metastases: NXP800 for the Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - May 20, 2024
P1, N=30, Not yet recruiting, Sponsor: Mayo Clinic
- | VK-2019 / Cullinan Oncology
Journal: Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. (Pubmed Central) - Nov 9, 2023
Not yet recruiting --> Recruiting VK-2019 was stable in plasma at -70
- VK-2019 / Cullinan Oncology
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies. (On Demand | Hall A; Poster Bd # 27) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3811;
P2
An MTD has not been yet established. Preliminary results indicate a decrease in EBV copy number and viral gene expression in latently infected tumor cells in some patients.
- | VK-2019 / The Wistar Institute, Stanford University
Enrollment open, Trial initiation date: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (clinicaltrials.gov) - Dec 16, 2021
P2, N=30, Recruiting, Sponsor: Stanford University
Preliminary results indicate a decrease in EBV copy number and viral gene expression in latently infected tumor cells in some patients. Not yet recruiting --> Recruiting | Initiation date: Aug 2021 --> Dec 2021
- | VK-2019 / The Wistar Institute, Stanford University
New P2 trial: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (clinicaltrials.gov) - Jun 14, 2021
P2, N=30, Not yet recruiting, Sponsor: Stanford University
- | VK-2019 / The Wistar Institute, Stanford University
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=14, Terminated, Sponsor: Cullinan Oncology, LLC
Not yet recruiting --> Recruiting | Initiation date: Aug 2021 --> Dec 2021 N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy
- || VK-2019 / The Wistar Institute, Stanford University
Enrollment closed: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Jun 17, 2020
P1/2, N=60, Active, not recruiting, Sponsor: Cullinan Apollo Corporation
N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy Recruiting --> Active, not recruiting
- | VK-2019 / The Wistar Institute, Stanford University
Trial completion date: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Mar 30, 2020
P1/2, N=60, Recruiting, Sponsor: Cullinan Apollo Corporation
Recruiting --> Active, not recruiting Trial completion date: Jan 2022 --> Jun 2023
- | VK-2019 / The Wistar Institute, Stanford University
Enrollment open: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Apr 8, 2019
P1/2, N=60, Recruiting, Sponsor: Cullinan Apollo Corporation
Trial completion date: Jan 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- | VK-2019 / The Wistar Institute, Stanford University
Trial completion date, Trial primary completion date: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Feb 28, 2019
P1/2, N=60, Not yet recruiting, Sponsor: Cullinan Apollo Corporation
Not yet recruiting --> Recruiting Trial completion date: Dec 2025 --> Jan 2022 | Trial primary completion date: Dec 2024 --> Oct 2021
- | VK-2019 / The Wistar Institute, Stanford University
New P1/2 trial: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Sep 24, 2018
P1/2, N=50, Not yet recruiting, Sponsor: Troy Messick